In Vitro Cytotoxicity of Human Endothelial Cells in Polymyalgia Rheumatica and Giant Cell Arteritis

Overview

Journal Rheumatol Int

Specialty Rheumatology

Date 1982 Jan 1

PMID 7163734

Citations 2

Authors

T S Bocanegra

B F Germain

H I Saba

P H Bridgeford

S R Saba

M B Lowenstein

F B Vasey

L R Espinoza

Affiliations

Soon will be listed here.

Abstract

We studied sera from 20 patients with polymyalgia rheumatica (PMR)/giant cell arteritis (GCA), 15 patients with systemic lupus erythematosus (SLE), 15 patients with the CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangietasia) and 33 age and sex matched controls for cytotoxicity against human endothelial cells using a 51Cr release assay. We observed increased levels of endothelial cytotoxic activity in the PMR/GCA sera compared with controls (P less than 0.001). This cytotoxicity was predominantly found in the GCA group, where 7 out of 10 patients (70%) demonstrated significant cytotoxicity. Sequential studies showed that the cytotoxic activity returned to normal when the disease was under control. Although 7 SLE and 3 CREST sera had significant cytotoxic activity, as a group they did not differ from controls (P less than 0.05). Pre-incubation with soybean trypsin inhibitor suppressed the cytotoxic activity in the positive sera suggesting the cytotoxicity is mediated via a protease mechanism. Our results demonstrate the presence of a cytotoxic factor in the serum of patients with PMR/GCA which may play an important role in the pathogenesis of the vascular lesions observed in these disorders.

Citing Articles

Fibrin(ogen)olysis in polymyalgia rheumatica and temporal arteritis: preliminary findings on association with disease activity.

Grau R, Kassan S, Franks J, Kaplan H, Walker S, Tan E Ann Rheum Dis. 1984; 43(5):721-4.

PMID: 6497463 PMC: 1001515. DOI: 10.1136/ard.43.5.721.

Endothelial cell cytotoxicity in inflammatory vascular diseases--the possible role of oxidised lipoproteins.

Blake D, Winyard P, SCOTT D, Brailsford S, Blann A, Lunec J Ann Rheum Dis. 1985; 44(3):176-82.

PMID: 3977420 PMC: 1001600. DOI: 10.1136/ard.44.3.176.

References

Bacon P, Doherty S, Zuckerman A . Hepatitis-B antibody in polymyalgia Rheumatica. Lancet. 1975; 2(7933):476-8. DOI: 10.1016/s0140-6736(75)90547-4. View

Espinoza L, Bridgeford P, Lowenstein M, Bocanegra T, Vasey F, Germain B . Polymyalgia rheumatica and giant cell arteritis: circulating immune complexes. J Rheumatol. 1982; 9(4):556-60. View

Thorgeirsson G, ROBERTSON Jr A . The vascular endothelium-pathobiologic significance. Am J Pathol. 1978; 93(3):803-48. PMC: 2018350. View

Plouvier B, Wattre P, Devulder B . HBs Ag in superficial artery of patient with polymyalgia rheumatica. Lancet. 1978; 1(8070):932-3. DOI: 10.1016/s0140-6736(78)90703-1. View

Hazleman B, MacLennan I, Esiri M . Lymphocyte proliferation to artery antigen as a positive diagnostic test in polymyalgia rheumatica. Ann Rheum Dis. 1975; 34(2):122-7. PMC: 1006359. DOI: 10.1136/ard.34.2.122. View

Huston K, Hunder G, Lie J, Kennedy R, ELVEBACK L . Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med. 1978; 88(2):162-7. DOI: 10.7326/0003-4819-88-2-162. View

Kahaleh M, Osborn I, LeRoy E . Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med. 1981; 94(4 pt 1):482-4. DOI: 10.7326/0003-4819-94-4-482. View

Hazleman B, Goldstone A, Voak D . Association of polymyalgia rheumatica and giant-cell arteritis with HLA-B8. Br Med J. 1977; 2(6093):989-91. PMC: 1631778. DOI: 10.1136/bmj.2.6093.989. View

Bird H, Esselinckx W, DIXON A, Mowat A, WOOD P . An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis. 1979; 38(5):434-9. PMC: 1000388. DOI: 10.1136/ard.38.5.434. View

10.

Papaioannou C, Hunder G, MCDUFFIE F . Cellular immunity in polymyalgia rheumatica and giant cell arteritis: lack of response to muscle or artery homogenates. Arthritis Rheum. 1979; 22(7):740-5. DOI: 10.1002/art.1780220708. View

11.

Saba H, Hartmann R, Saba S . Effects of polymorphonuclear leukocytes on endothelial cell growth. Thromb Res. 1978; 12(3):397-407. DOI: 10.1016/0049-3848(78)90311-0. View

12.

Cohen A, Canoso J . Criteria for the classification of systemic lupus erythematosus--status 1972. Arthritis Rheum. 1972; 15(5):540-3. DOI: 10.1002/art.1780150512. View

13.

Bridgeford P, Lowenstein M, Bocanegra T, Vasey F, Germain B, Espinoza L . Polymyalgia rheumatica and giant cell arteritis: histocompatibility typing and hepatitis-B infection studies. Arthritis Rheum. 1980; 23(4):516-8. DOI: 10.1002/art.1780230417. View

14.

Hamilton Jr C, SHELLEY W, Tumulty P . Giant cell arteritis: including temporal arteritis and polymyalgia rheumatica. Medicine (Baltimore). 1971; 50(1):1-27. View

15.

Rosenthal M, Muller W, Albert E, Schattenkirchner M . Letter: HL-A antigens in polymyalgia rheumatica. N Engl J Med. 1975; 292(11):595. DOI: 10.1056/nejm197503132921121. View

16.

Kahaleh M, Sherer G, LeRoy E . Endothelial injury in scleroderma. J Exp Med. 1979; 149(6):1326-35. PMC: 2184886. DOI: 10.1084/jem.149.6.1326. View

17.

Papaioannou C, Gupta R, Hunder G, MCDUFFIE F . Circulating immune complexes in giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 1980; 23(9):1021-5. DOI: 10.1002/art.1780230909. View

18.

Hunder G, Taswell H, Pineda A, ELVEBACK L . HLA antigens in patients with giant cell arteritis and polymyalgia rheumatica. J Rheumatol. 1977; 4(3):321-3. View

19.

Liang M, Greenberg H, Pincus T, ROBINSON W . Letter: Hepatitis-B antibody in polymyalgia rheumatica. Lancet. 1976; 1(7949):43. DOI: 10.1016/s0140-6736(76)92944-5. View

20.

Sorensen S, Lorenzen I . Giant-cell arteritis, temporal arteritis and polymyalgia rheumatica. A retrospective study of 63 patients. Acta Med Scand. 1977; 201(3):207-13. DOI: 10.1111/j.0954-6820.1977.tb15683.x. View